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Abstract
Protein phosphorylation is a common post-translational modification in eukaryotic cells and has a wide range of functional
effects. Here, we used mass spectrometry to search for phosphorylated residues in all the proteins of influenza A and B
viruses – to the best of our knowledge, the first time such a comprehensive approach has been applied to a virus. We
identified 36 novel phosphorylation sites, as well as confirming 3 previously-identified sites. N-terminal processing and
ubiquitination of viral proteins was also detected. Phosphorylation was detected in the polymerase proteins (PB2, PB1 and
PA), glycoproteins (HA and NA), nucleoprotein (NP), matrix protein (M1), ion channel (M2), non-structural protein (NS1) and
nuclear export protein (NEP). Many of the phosphorylation sites detected were conserved between influenza virus genera,
indicating the fundamental importance of phosphorylation for all influenza viruses. Their structural context indicates roles
for phosphorylation in regulating viral entry and exit (HA and NA); nuclear localisation (PB2, M1, NP, NS1 and, through NP
and NEP, of the viral RNA genome); and protein multimerisation (NS1 dimers, M2 tetramers and NP oligomers). Using
reverse genetics we show that for NP of influenza A viruses phosphorylation sites in the N-terminal NLS are important for
viral growth, whereas mutating sites in the C-terminus has little or no effect. Mutating phosphorylation sites in the
oligomerisation domains of NP inhibits viral growth and in some cases transcription and replication of the viral RNA
genome. However, constitutive phosphorylation of these sites is not optimal. Taken together, the conservation, structural
context and functional significance of phosphorylation sites implies a key role for phosphorylation in influenza biology. By
identifying phosphorylation sites throughout the proteomes of influenza A and B viruses we provide a framework for further
study of phosphorylation events in the viral life cycle and suggest a range of potential antiviral targets.
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Introduction
Influenza viruses cause serious and widespread disease in
humans and livestock. Influenza A viruses can infect a wide range
of birds and mammals, including humans [1]. Adaptation of novel
influenza A viruses to humans appears to have caused pandemics
for much of recorded history, including those of the devastating
1918 ‘Spanish’ influenza and the recent 2009 swine-origin
influenza virus [2]. Established influenza A virus strains are
responsible for seasonal influenza epidemics in humans, with
additional cases of seasonal influenza caused by influenza B
viruses, which have a much more restricted host range [3].
Humans are also infected by influenza C viruses, which typically
only cause mild infections [4].
The proteins encoded by influenza viruses undergo a variety of
post-translational modifications. In eukaryotic cells, phosphoryla-
tion of serine, threonine or, less frequently, tyrosine, is a common
reversible protein modification that can have a wide range of
effects on activity, stability, subcellular localisation and protein-
protein interactions [5]. Phosphorylation can be readily detected
using classical biochemical techniques, and a number of studies
have identified phosphorylation of influenza virus proteins [6–23].
However, it is difficult to determine specific sites of phosphory-
lation using such techniques [24] and, to date, relatively few sites
of influenza virus phosphorylation have been identified. In
influenza A viruses phosphorylation has been found at T157 in
the polymerase protein PA [25], T27 and S35 in the virulence
factor PB1-F2 [16], S3 in the nucleoprotein (NP) [7,13], S64, S82,
S89, and S93 in the ion channel M2 (with S64 the major site of
phosphorylation) [11] and S42, S48 and T215 in the non-
structural protein NS1 [26,27]. In addition, phosphorylation has
been identified for S78 and S103 of influenza C virus M2, with
S78 the major site of phosphorylation [28].
Here, we use liquid chromatography and tandem mass
spectrometry (LC-MS/MS) to search for sites of phosphorylation
in the proteomes of influenza A and B viruses. The same approach
also allowed N-terminal processing to be identified, as well as a site
of ubiquitination (in the influenza B virus M1 protein). To the best
of our knowledge, this is the first time mass spectrometry has been
used to simultaneously assess the phosphorylation of all proteins in
a virus. In addition to three previously-identified sites, we report
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22 novel sites of phosphorylation in influenza A viruses and14
novel sites of phosphorylation in influenza B viruses. Comparisons
of experimental data and consensus sequences show that
phosphorylation sites are conserved within and in some cases
between genera. As the influenza A and B virus genera are
estimated to have diverged several thousand years ago [29,30], this
conservation shows the fundamental importance of phosphoryla-
tion in influenza virus life cycles and identifies numerous potential
targets for specific antiviral inhibition.
In the following sections we give an overview of the viruses and
methodologies used in the study, give details of N-terminal
processing of viral proteins, and then describe the location of
phosphorylation sites in the matrix protein M1 and the ion
channel M2, in the non-structural protein NS1 and the nuclear
export protein NEP, in the viral glycoproteins, and in the
polymerase and NP. By analysing the conservation and structural
context of phosphorylation sites we propose that in influenza A
and B viruses phosphorylation sites can affect viral entry and exit
(HA and NA), regulate nuclear localisation (PB2, NP, M1, NEP,
and possibly PB1 and NS1) and affect protein multimerisation
(NP, M2 and NS1). Finally, we present experimental evidence that
phosphorylation sites in influenza A virus NP contribute to viral
growth in tissue culture and play a role at various points in the
viral life cycle.
Results/Discussion
Overview of the Viruses and Methodologies Used in the
Study
For influenza A viruses, we focussed on the well-studied H1N1
laboratory strain A/WSN/33 (WSN), using virions purified from
the growth media of infected MDBK cells (Figure 1). In addition to
the laboratory-adapted WSN virus, candidate vaccine viruses
(CVVs) were considered. Influenza A CVVs were reassortants of
the H1N1 laboratory strain influenza A/Puerto Rico/8/1934
(PR8) with clinical isolates of pandemic H1N1 and seasonal H3N2
viruses (Figure S1A; see Materials and Methods for details). CVV
samples consisted of virions purified from embryonated chicken
eggs and also (in one case) from the growth media of infected
MDCK cells. For an influenza B virus, the directly egg-adapted
CVV influenza B/Brisbane/60/2008 was used, purified from
embryonated chicken eggs. Purification of viral proteins was
assessed by PAGE and Coomassie or silver staining, which
demonstrated the presence of highly concentrated viral proteins
and the exclusion of the majority of cellular contaminants
(Figures 1A, S1A). Purified influenza WSN virus was visualised
by negative-staining and transmission electron microscopy, dem-
onstrating intact virions of the expected morphology, with little
contaminating material (Figure 1B). For purified virions, the entire
protein content of the sample was processed without fractionation.
In addition to protein harvested from virions, proteins of the
WSN virus were purified from lysates of human 293 T cells and
from MDBK cells. In one approach tagged PB2 was used to purify
material from infected cells (Figure S1B); all co-purifying proteins
were analysed. In an alternative approach material co-purified
with tagged proteins from transfected cells (Figure S1C) or
unpurified lysates of infected cells (data not shown), were separated
by PAGE, and bands were cut at the appropriate position to
obtain the major viral proteins. Phosphorylation can alter
electrophoretic mobility, and it is possible that cutting bands
would cause modified proteins to be missed. In an attempt to
counter this, Coomassie staining was used to identify the required
proteins in the gel (data not shown).
Proteins were prepared for mass spectrometry by either excising
them from polyacrylamide gels or by precipitation. Proteins were
digested with trypsin to produce charged peptides, which were
analysed by LC-MS/MS using the Central Proteomics Facilities
Pipeline (CPFP) [31]. Localisation of phosphorylation sites was
assessed using the Modification Localisation Score (ModLS) tool
within CPFP, which is based on the PTMScore and AScore
methods [32,33]. To determine the most probable localisations for
each phosphopeptide, ModLS scored all possible localisations
using the mass-spectral evidence (see Materials and Methods for
details). Detecting and identifying phosphorylated peptides by
mass spectrometry has inherent difficulties [24], and initially we
identified only a small number of sites. During the course of the
investigation, the introduction of improved protocols and
technology (notably, enrichment for phosphopeptides using TiO2
or IMAC resin, and the use of a more sensitive mass spectrometer,
Figure 1. Purification of viral proteins. (A) Purification of WSN virus
from the growth medium of infected MDBK cells. Samples of unpurified
and purified material (0.01 ml from 120 ml and from 0.14 ml,
respectively) were separated by 12% SDS-PAGE and stained with
Coomassie Brilliant Blue. Key proteins are identified by electrophoretic
mobility. (B) Negative-stain transmission electron micrographs of
purified WSN virus. Two different magnifications are shown.
doi:10.1371/journal.ppat.1002993.g001
Author Summary
Eukaryotic cells regulate the function of many of their
proteins through the reversible phosphorylation of serine,
threonine or tyrosine residues. It is known that some
influenza virus proteins are phosphorylated, but few sites
of phosphorylation have been identified. We used mass
spectrometry to identify 39 sites of phosphorylation, most
of them novel, in proteins from influenza A viruses and an
influenza B virus (a separate genus in the orthomyxovirus
family) - to the best of our knowledge, this is the first time
this has been attempted for all the proteins in a virus. By
integrating sequence conservation data and structural
information we were able to propose functions for most of
these sites, providing a foundation for further studies, and
we assessed experimentally the contribution of multiple
phosphorylation sites in the influenza A virus nucleopro-
tein (NP) to viral growth and to transcription and
replication of the genome. In addition, by identifying
phosphorylation sites that are common to both influenza
A and B viruses, we suggest that phosphorylation at these
sites is a highly conserved aspect of influenza biology that
may provide targets for antiviral therapy.
Protein Phosphorylation in Influenza Viruses
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referred to in the text as ‘optimised methods’) greatly increased the
number of phosphorylation sites detected. The phosphorylation
sites found in influenza A and B viruses are summarised in Tables 1
and 2, respectively. Details of protein sequence coverage for all
combinations of viruses and hosts are given in Table S1 and Figure
S2, and details of phosphorylation sites found using different
methods are given in Table S2. Representative fragment spectra
for each modification identified are given in Figure S3. In all cases
peptides containing the unmodified site were also identified.
When analysing WSN and B/Brisbane/60/2008 virions, we
pooled data from multiple experiments, providing between 43%
and 94% coverage of each protein detected, with each tryptic
peptide detected an average of 18 times (Table S1). For WSN, the
database of proteins searched included all known viral proteins, as
well as the translations of hypothetical open reading frames. No
peptides were found from PB1-F2, or the putative ambisense gene
product NSP/NEG8 [34,35], and no peptides were found
matching the unique sequences of the PA-X [36] or PB1-N40
proteins [37]. Somewhat surprisingly, the non-structural protein
NS1 was readily detected in all preparations of influenza A and B
viruses. While attempts were made to achieve a high degree of
viral purity (Figure 1) the current study cannot definitively
distinguish structural proteins from carry-over of unincorporated
proteins, and it is possible that NS1 was present in cellular debris
that was co-purified with the virus. Consistent with this hypothesis,
label-free quantitation (by SINQ [38] and iBAQ [39], data not
shown) suggested that NS1 was found in the samples only at a low
level, similar to that of many host proteins.
N-terminal Acetylation and Methionine Excision
In addition to phosphorylation it was possible to detect N-
terminal acetylation and methionine excision, which are both
common post-translational modifications in eukaryotic cells [40].
While N-terminal acetylation has been linked to specific functions
for a small number of proteins, its clearest general function is in
preventing protein degradation [41]. As described in Tables 3 and
S3, we detected N-terminal peptides from PB1, PA, NP, M1, M2,
NS1 and NEP of influenza A virus and from PA, NP, M1, NS1
and NEP of influenza B virus, and in all cases N-terminal
Table 1. Summary of influenza A virus phosphorylation sites.
Protein
Putative phosphorylation
site
Peptide
Identification
Probabilitya
Residue Conservation
(%) Kinase predictionsb Samplec Ref
PB2 S742 1.000 99.9 PKA, PKB, RSK S
PB1 T223 0.985 99.8 N T
PA S224/S225 0.998 99.5/69.2 N/N S
HA T358 1.000 99.6 N V
NP S9/Y10 1.000 99.1/99.99 CKI, PKA/INSR V, S
S165 0.999 99.9 PKA V, S
Y296/S297 1.000 99.9/99.98 P/Cdc2 S
S377/T378 0.798 58.6/99.95 CKII/N S
S402/S403 0.999 99.9/0.1 PKC/PKA V, E, S, T
S457 0.970 99.97 N V
T472/S473 1.000 96.0/2.83 N/GSK3 V
NA S160/S164/S166 0.991 99.8/99.98/99.8 PKA, RSK/N/N V
M1 S2/T5 0.968 99.97/99.91 PKA/N V, E
T9/Y10 1.000 98.5/98.5 N/N V, E
T37 1.000 98.6 CKII, PKG V, E
T108 0.978 99.97 CKI V
T168/T169 0.981 93.1/99.9 P/N V
S195/S196 1.000 99.9/99.8 CKI/N V
S224/S225/S226 1.000 92.3/98.7/99.97 N/Cdc2/P V
M2 S64/T65 0.998 98.4/99.4 PKA/P V, E [11]
S64 and T65 0.995 98.4/99.4 PKA/P V
NS1 S48 1.000 45.1 PKA 2 [27]
T197 0.996 37.8 N V
T215 1.000 27.1 Cdk5, GSK3, p38MAPK V, 2, M [26,27]
NEP S23/S24/S25 1.000 99.2/99.8/99.8 CKII/P/CKII V
NB: Residue conservation was calculated for H1-subtype HA and N1-subtype NA.
P =phosphorylation predicted by NetPhos 2.0, with no kinase predicted by NetPhosK 1.0.
N = no phosphorylation predicted.
aof clearest peptide spectral match.
bfrom WSN sequence.
cV: purified WSN virus, S: PB2-CStrep purification from an infection, T: TAP purification from a transfection, E: purified egg-grown CVV, 2: 293 T cell lysates, M: MDCK cell
lysates.
doi:10.1371/journal.ppat.1002993.t001
Protein Phosphorylation in Influenza Viruses
PLOS Pathogens | www.plospathogens.org 3 November 2012 | Volume 8 | Issue 11 | e1002993
processing was detected. In most cases it is unclear whether N-
terminal modifications would affect the function of these proteins,
though structural studies suggest that N-terminal acetylation or
methionine excision of PB1 should not affect its ability to interact
with PA (data not shown; [42,43]).
Phosphorylation of the Viral Matrix Protein M1 and the
Ion Channel M2
The matrix protein M1 of influenza A and B viruses is known to
be phosphorylated at multiple sites, predominantly serines but also
threonine [9,10]. M1 is the most abundant protein in the virus
(Figure 1A) [44], and the sequence coverage of M1 was the highest
of any protein analysed (Table S1).
For influenza A viruses, even without enrichment for phospho-
peptides we detected phosphorylation in the N-terminus of WSN,
though it was unclear from the mass spectrum whether this was at
T9 or Y10. Using optimised conditions, we again detected
phosphorylation at this position, with phosphorylation of Y10
giving the best match to the observed mass spectrum (Tables 1,
S2). We also detected phosphorylation at S2/T5, T108, T168/
T169, S195/S196 (S195 has previously been noted to be in the S-
x-E recognition motif of casein kinase [22,45]), and S224/S225/
S226 (with S226 matching the spectrum best; Table S2). In the
PR8-derived M1 proteins of influenza A CVVs, even without
using optimised conditions we once again detected phosphoryla-
tion at S2/T5 (or potentially at T9/Y10) and at S224/S225/S226,
and we also detected phosphorylation at T37.
For the influenza B virus we observed a similar pattern of M1
phosphorylation. Without using optimised conditions we detected
phosphorylation in the N-terminus, most likely at S2 or T7,
though its localisation to Y10 cannot be ruled out (Tables 2, S2).
With optimised conditions we detected this site again, with
additional phosphorylations at residues S41, S84/T88/T89/T91,
S214/S218, and S236/S237. We also detected phosphorylation at
T188, on two peptides which also had di-glycine conjugated to the
side-chain of either K194 or K200. Tryptic digestion of
Table 2. Summary of influenza B virus phosphorylation sites.
Protein Putative phosphorylation site
Peptide
Identification
Probabilitya Residue Conservation (%) Kinase predictions
HA S135/T136 0.913 100/98.2 PKA, PKC/PKC
S465 1.000 100 ATM, CKI
NP S50 0.999 100 GSK3, Cdk5
T55/T56/S57/S58 0.999 99.6/99.4/79.7/88.8 Cdc2/CKII, PKG/P/CKI, CKII
S223 1.000 100 N
Y352/Y357/Y363 0.926 100/100/100 P/P/N
S459/S463/S465 1.000 100/99.6/99.8 N/N/Cdc2, Cdk5, p38MAPK
S486 1.000 98.9 PKA, RSK
M1 S2/T7/Y10 0.983 100/100/100 CKI, PKA/N/N
S41 0.922 100 CKI, CKII
S84/T88/T89/T91 0.862 100/100/100/100 Cdc2/PKC/Cdc2, PKC/PKC
T188 + K194/K200 (Ub) 0.999 99.8+100/99.1 PKC
S214/S218 0.996 100/99.8 PKC/ATM
S236/S237 0.898 100/100 Cdc2/PKA
P=phosphorylation predicted by NetPhos 2.0, with no kinase predicted by NetPhosK 1.0.
N = no phosphorylation predicted.
aof clearest peptide spectral match.
doi:10.1371/journal.ppat.1002993.t002
Table 3. Summary of N-terminal modifications.
Protein None Methionine excision N-terminal acetylation
Methionine excision + N-
terminal acetylation
PB1 A A
PA A+B
NP A+B
M1 A+B A+B A+B A+B
M2 A A
NS1 A B
NEP A A B
A: detected in influenza A virus.
B: detected in influenza B virus.
doi:10.1371/journal.ppat.1002993.t003
Protein Phosphorylation in Influenza Viruses
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conjugated ubiquitin leaves a di-glycine tag on the ubiquitinated
protein. This modification therefore provides evidence that M1 of
influenza B virus can be ubiquitinated at either K194 or K200.
M1 of influenza A virus was recently shown to be ubiquitinated
[46]; this observation shows that influenza B virus M1 is also
ubiquitinated and for the first time identifies a site of ubiquitina-
tion in an influenza M1 protein.
Comparison of the sites of phosphorylation in M1 proteins of
influenza A and B viruses indicates a number of common features
(Figure 2A). In alignments of the primary sequences, we found
four phosphorylation sites at similar positions in both genera.
These are the sites in the N-terminal 10 amino acids, at T37 (A)/
S41 (B) (both predicted to be targets of the kinase CKII; Tables 1,
2), at S195/S196 (A)/T188 (B) and at S224-S226 (A)/S214/S218
(B). In addition, three sites (T108 (A), T168/T169 (A) and S236/
S237 (B)), are close to a serine, threonine or tyrosine in the other
genus which could potentially be phosphorylated. Only one of the
sites detected (S84-T91 (B)) does not correspond to a possible site
of phosphorylation in the other genus. Thus, despite estimates that
influenza A and B viruses have been evolving as separate genera
for several thousand years [29,30] their patterns of M1 phosphor-
ylation appear to have been conserved.
The N-terminal domain of influenza A virus M1 has been
crystallised and has a flattened shape, with its opposing faces being
positively and negatively charged [47,48]. The phosphorylation of
S2, T5, T9 or Y10 would contribute to the net negative charge of
one face of M1 (Figure 2B). It has been proposed that M1 may
undergo a conformational change to bind to the inner leaflet of the
plasma membrane, exposing hydrophobic residues in helix 1 and
helix 4 [48]. S2, T5, T9 and Y10 are oriented away from the
hydrophobic face of helix 1, and so their phosphorylation would
not necessarily prevent lipid binding (Figure 2B). It is probable that
these residues account for biochemical observations that a major
site of M1 phosphorylation lies within or close to a stretch of
hydrophobic residues [10]. A similar pattern of charged and
hydrophobic residues, and of potential sites of phosphorylation, is
conserved in the N-terminal M1 sequences of influenza A and B
viruses (Figure 2A), though not in influenza C viruses (data not
shown).
T37 and T108 both form part of another surface of the N-
terminal domain, in this case in loops that pass between the
positively and negatively charged faces (Figure 2B). T108 is close
to the NLS of M1 (Figure 2B; [49]). An identical spacing can be
seen in M1 of influenza B viruses between basic residues
orthologous to this NLS (presumably the influenza B virus M1
NLS) and a conserved serine (S108; Figure 2A). This pattern is not
seen in influenza C viruses (data not shown). Phosphorylation at or
adjacent to NLSs is an important regulator of nuclear import,
acting through a range of stimulatory and inhibitory mechanisms
[50–52]. The conserved spacing of an NLS and a nearby
phosphorylation site in influenza A and B viruses suggests a role
for phosphorylation in regulating the nuclear import of M1,
though whether phosphorylation in this context promotes or
inhibits nuclear import remains to be determined.
The C-terminal domain of influenza A virus M1 has not been
resolved by X-ray crystallography, but a combination of modelling
and experimental studies suggest that it consists of alpha helices
connected by loops [53]. Comparing N- and C-terminal secondary
structures to the phosphorylation sites shows that, with the
exception of phosphorylations in the N-terminal helix 1,
phosphorylations throughout M1 take place on loops (data not
shown).
The M2 protein forms a tetrameric ion channel in the viral
envelope and is subject to a number of post-translational
modifications, including disulphide bond formation, palmitoyla-
tion, fatty acylation, and phosphorylation [11,54]. Previous studies
have shown that for influenza A viruses the majority of M2
phosphorylation takes place at S64 [11,21].
We clearly detected phosphorylation of either S64 or T65 in M2
of influenza A viruses even, in the case of the PR8-derived M2 of
the CVVs, without using optimised conditions (Tables 1, S2).
While some spectra favoured assignment of the phosphorylation to
S64, others were ambiguous as to whether S64 or T65 was
modified. Using optimised conditions, we detected a peptide in
which S64 and T65 were simultaneously phosphorylated (Table 1).
While consistent with previous data suggesting that the majority of
M2 phosphorylation is of S64, this demonstrates that phosphor-
ylation of T65 is also possible.
Figure 2. Location of phosphorylated residues in the matrix
protein M1 and the ion channel M2. (A) The M1 consensus
sequences of influenza A and B viruses, aligned using ClustalW2. Letters
are coloured green for experimentally-confirmed phosphorylation sites,
blue for the nuclear localisation signal (NLS) of influenza A virus and
orthologous basic residues in influenza B virus, and purple for a
ubiquitination site. Where modifications could be assigned to more
than one residue, all probable residues are coloured (see text for
details). Confirmed phosphorylation sites, and their possible ortholo-
gues, are highlighted in green. (B) Location of phosphorylated residues
in the N-terminal portion of influenza A virus M1 (PDB 1EA3 [47]).
Hydrophobic residues in helices 1 and 4 are coloured yellow and basic
residues of the NLS dark blue. (C) Sections of the M2 consensus
sequences of influenza A, B and C viruses. Colours are as (A), with
additional highlighting of structural features: alpha helices are orange
(where experimentally determined; PDB 2L0J [57] and PDB 2KJ1 [56]) or
yellow (where predicted by JPred 3), and a beta sheet is purple
(predicted by JPred 3).
doi:10.1371/journal.ppat.1002993.g002
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The M2 protein is translated from a spliced version of the
mRNA encoding M1, with splicing taking place in codon nine of
the M1 open reading frame. As the nine N-terminal residues
common to M1 and M2 do not include a tryptic cleavage site, the
N-termini of the two proteins could be clearly distinguished in this
study. Despite being common to both proteins, residues S2/T5
and T9 are phosphorylated in M1 but not in M2. This is
presumably a difference in phosphorylation, due to the different
N-terminal structures of the two proteins. However, we cannot
exclude the possibility that this difference is due to a chance failure
to detect phosphorylated M2 peptides.
The M2 proteins of influenza A, B and C viruses are all
phosphoproteins [11,28,55], but have little primary sequence
homology ([56] and data not shown). By combining partial
structures of the influenza A virus M2 and influenza B virus BM2
cytoplasmic domains [56,57] with structures predicted from the
primary sequence of influenza A and C viruses, we found that in
all three genera the cytoplasmic tail contains a loop between two
alpha helices, within which is a conserved S-x-E casein kinase
recognition motif (Figure 2C; [45]). The phosphorylation predic-
tion methods NetPhos 2.0 and NetPhosK 1.0 [58] predict
phosphorylation for all three serines – S64 in influenza A viruses,
S91 in influenza B viruses and S78 in influenza C viruses.
Phosphorylation of influenza BM2 was not detected in this study,
but S64 and S78 are known to be the primary sites of M2
phosphorylation in influenza A and C viruses, respectively [11,28].
Thus, phosphorylation of a cytoplasmic loop in M2 appears to be
a general feature of influenza viruses.
Mutating the cytoplasmic loop serine of influenza A and C
viruses reduces the ability of M2 dimers to assemble into tetramers
[21,28]. In influenza A viruses this does not appear to inhibit viral
replication in cell culture or in experimentally infected mice [21],
but these systems are more permissive to viral growth than natural
infections [21], and although the mutation prevented the majority
of M2 phosphorylation it is possible that low levels of T65
phosphorylation may have reduced any phenotype further. It is,
therefore, plausible that phosphorylation of a loop in the
cytoplasmic tail of M2 promotes tetramer formation in influenza
A, B and C viruses.
Phosphorylation of the Non-Structural Protein NS1 and
the Nuclear Export Protein
The non-structural protein NS1 is known to be phosphorylated,
predominantly on threonine [9,17,18,26,27], though the pattern
of phosphorylation may vary between strains [59]. In this study,
we detected three sites of phosphorylation in WSN NS1.
Phosphorylation of S48 was detected in the lysates of 293 T cells,
phosphorylation of T197 in preparations of WSN virus, and
phosphorylation of T215 in lysates of 293 T and MDBK cells, as
well as (with a weaker spectrum) in preparations of WSN virus
(Tables 1, S2).
A recently published report noted phosphorylation of S48 [27],
observing that although it is part of the RNA-binding domain of
NS1, it is positioned so that it does not participate in RNA binding
(Figure 3A, [60]). Mutational analysis suggested that phosphory-
lation at S48 does not affect virus replication in tissue culture;
consistent with this, the residue is asparagine in a number of
human isolates [27]. T197 is part of the NS1 effector domain
(Figure 3B). With the nearby S195, it makes strong hydrogen-
bonding interactions with D92, a virulence determinant in H5N1
strains of the virus, and it is adjacent to the dimer interface of NS1
effector domains [61]. It has been proposed that phosphorylation
of either S195 or T197 may destabilise NS1, potentially disrupting
its dimerisation [61], and may regulate its nuclear localisation
[62]. T215 is in the disordered C-terminal tail of NS1 [62], and is
adjacent to a second NLS in some strains of the virus – though not
in WSN [63]. Phosphorylation of T215 has previously been
detected, but although the residue is important for viral growth,
mutational analysis suggests that its phosphorylation is not
required in tissue culture [26,27].
The nuclear export protein (NEP) of influenza A and B viruses is
involved in the nuclear export of the viral genome in the form of
ribonucleoprotein complexes (RNPs) [64–66] and despite initial
descriptions of it as a second non-structural protein (NS2) it has
been shown to be incorporated into virions [19,67,68]. The NEP
of influenza A virus is known to be phosphorylated [19]. Both with
and without optimised conditions, we detected phosphorylation in
the NEP of WSN at S23, S24 or S25 (Table 1). In the clearest
Figure 3. Location of phosphorylated residues in the non-
structural protein NS1 and the nuclear export protein NEP. (A)
Location of S48 in the dimeric NS1 RNA binding domain (PDB 2ZKO
[60]). The subunits of the dimeric NS1 RNA binding domain are shown
in light blue and pink, and RNA in gold. (B) Location of T197 and
interacting residues in the dimeric NS1 effector domain (PDB 2GX9 [61]).
(C) Consensus sequences of the N-terminal residues of influenza A and
B virus NEP. Colours are as in Figure 2, with key hydrophobic residues of
the nuclear export signal (NES) in red.
doi:10.1371/journal.ppat.1002993.g003
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spectra S24 is unambiguously phosphorylated but in others the
localisation is less distinct, and phosphorylation of S23 or S25 in a
proportion of cases cannot be excluded.
The NEP phosphorylation site is adjacent to a previously
identified nuclear export signal (NES) [64,65] (Figure 3C), and is
predicted to lie on a loop between an N-terminal alpha helix
containing the NES and another alpha helix. The same
arrangement of three serines or threonines with respect to the
NES and to predicted alpha helices is found in NEP of influenza B
viruses (Figure 3C; phosphorylated peptides were not detected
from influenza B virus NEP in this study), though not in influenza
C viruses where the NES is located in a different region of the
protein [66].
As with NLSs, phosphorylation in or near to NESs can promote
or inhibit nuclear export through a range of mechanisms [51,52].
The conserved spacing of the NES and phosphorylation site in
influenza A and B viruses (Figure 3C) suggests that phosphory-
lation regulates the interaction of NEP with its nuclear export
factor Crm1 [64]. Blocking activation of the MAP kinase ERK has
been shown to prevent the nuclear export of NEP, indicating that
phosphorylation has a stimulatory effect on the export of NEP,
and thereby of RNPs [69]. A possible mechanism for this is
suggested by the cellular MK2 protein, which also requires
phosphorylation for Crm1-mediated export. In MK2 the NES is
part of an autoinhibitory alpha helix that interacts with an
adjacent domain of the molecule. Phosphorylation of a hinge
region induces a conformational change, reducing the interaction
between the alpha helix and the rest of the molecule and
unmasking the NES [70,71]. The position of the NEP phosphor-
ylation site on a loop between the NES and an adjacent alpha
helix suggests that phosphorylation may unmask the NES in a
similar fashion. The nuclear export of RNPs necessarily precedes
viral assembly, and consistent with this phosphorylated NEP was
readily detected in virions of WSN (Table 1).
Phosphorylation of the Viral Glycoproteins
The haemagglutinin (HA) and neuraminidase (NA) proteins of
influenza viruses are known to be subject to post-translational
modification, notably glycosylation [72–74], but we were not
aware of reported phosphorylation of these proteins. Indeed, we
found comparatively few sites of phosphorylation in the glycopro-
teins, with modifications only detected when optimised conditions
for phosphopeptide detection were used (Table S2).
For HA of the influenza A virus WSN (H1 subtype), we detected
phosphorylation of T358. After cleavage of HA0, T358 forms
residue 15 of the fusion peptide of the HA2 fragment, which
inserts into the endosomal membrane to allow viral fusion
(Figure 4A) [72,75]. T358 is oriented away from the majority of
the hydrophobic residues in the fusion peptide, and is expected to
remain exposed to solvent during fusion rather than being buried
in the membrane [76]. As a result, the presence of a negatively-
charged phosphate at this position should not interfere with the
fusion process (Figure 4A, inset).
Residues in the fusion peptide, including T358 (Table 1), are
highly conserved among H1 haemagglutinins. When consensus
sequences of the fusion peptides of different HA subtypes from
influenza A and B viruses are compared, they conform to an
overall consensus sequence, with a small number of biochemically
conservative changes (Figure 4B). We found that the only position
not to conform to a clear overall consensus is position 15. This can
take the form of the potentially-phosphorylated, small polar
residues serine and threonine (H1, H6, H8 and H9 subtypes); of
Figure 4. Location of phosphorylated residues in haemagglutinin. (A) An influenza A virus H1-subtype HA monomer (PDB 1RVZ [75]) and an
influenza B virus HA monomer (PDB 2RFU [81]). In the influenza A virus HA, T358 is indicated in the N terminus of HA2 and, after conformational
rearrangement, in the fusion peptide (inset; PDB 2KXA [76]); the corresponding residue E377 is indicated in influenza B virus HA2. In influenza B virus
HA S135 in indicated in the head domain (in the structure shown, position 136 is alanine), and S465 in the stem; the corresponding E446 residue is
indicated in influenza A virus HA2. HA1 is shaded pink, HA2 light blue, hydrophobic residues of the fusion peptide yellow, glycosylations of the
influenza B HA orange, the a(2,6)-sialic acid-containing pentasaccharide LSTc red and glutamic acids orthologous to phosphorylation sites purple. (B)
The overall consensus sequence of the HA fusion peptide, compared to the consensus sequences of individual subtypes and lineages. Residue 15 of
the fusion peptide, which corresponds to T358 of the H1 sequence, is shaded.
doi:10.1371/journal.ppat.1002993.g004
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glutamic acid, which has similar physicochemical properties to
phosphoserine or phosphothreonine (H3, H7, H10 and H15
subtypes, as well as both influenza B virus lineages); of glutamine,
which is a similar size to glutamic acid but polar rather than
charged (H2, H4, H5, H14 and H17 subtypes); or of proline, a
small secondary amine which, unlike the other possibilities, is
hydrophobic (H11, H12, H13 and H16 subtypes). This diversity
between subtypes suggests that, unlike the rest of the fusion
peptide, position 15 can tolerate a range of physicochemical
properties. In support of this, an E15V mutation in the H3 fusion
peptide does not affect the fusogenic properties of HA [77]. It is
therefore likely that phosphorylation of T358 in H1 subtypes, as
detected here, would be compatible with HA function. Within
subtypes, however, position 15 is highly conserved, suggesting that
each subtype has an optimal amino acid.
Prior to fusion, HA is maintained in a metastable conformation
by hydrogen bonding between the fusion peptide and a pocket
formed from residues in both the HA1 and HA2 fragments.
Interactions between the fusion peptide and the pocket are
subtype-dependent, and disrupting these interactions by mutation
has been shown to regulate the pH at which HA is activated
[78,79]. A recent study showed that a threonine to isoleucine
mutation proximal to the fusion peptide was an important
determinant of the pH of HA activation and, consequently, of
the respiratory droplet transmissibility of an H5 HA/H1N1
reassortant virus in ferrets [80]. The presence of charged, polar or
hydrophobic amino acids at position 15, as shown here, would be
expected modulate the pH at which activation occurs for a given
HA subtype. If this is the case, phosphorylation of position 15
(possible for the H1, H6, H8 and H9 subtypes) could provide an
additional mechanism for fine-tuning the activation of HA.
In influenza B viruses position 15 of the fusion peptide is
glutamic acid (E377), and hence cannot be phosphorylated
(Figure 4A, B). However, two additional phosphorylation sites
were found. We detected phosphorylation in the HA1 fragment, at
one of two conserved residues, S135 or T136, and also in the HA2
fragment, at the conserved residue S465. The S135/T136 site,
which has no obvious ortholog in the influenza A virus HA
structure (Figure 4A), is surface-exposed on a loop in the head
domain of HA, away from the interface of the trimer subunits [81].
It is not part of the receptor binding site of HA, and so would not
be expected to interfere directly with sialic acid binding. It has,
however, been noted that in influenza A viruses the net charge of
the HA1 affects the ability of the virus to interact non-specifically
with negatively-charged cell surfaces [82,83]. The virus is known
to require a balance of HA and NA functional activity, and
charged amino acid substitutions reducing the binding affinity of
HA have been shown to compensate for mismatched NA activities
[84]. Phosphorylation of the S135/T136 site would be expected to
reduce the avidity of HA for cell surfaces. As only a proportion of
the viral HA is phosphorylated (unmodified peptides from the
same region were also detected) this suggests a novel mechanism,
of more subtle effect than the substitution of charged residues, for
achieving optimal HA activity.
Phosphorylation of S465 is harder to explain, as it is internal to
the HA trimer and unlikely to be accessible to kinases (Figure 4A).
S465 is in one of the short regions of primary sequence similarity
between influenza A and B virus haemagglutinins, and it is
orthologous to a glutamic acid present in all influenza A subtypes
(E446 in H1 subtypes; data not shown). At the pH of fusion
influenza A virus HA undergoes a drastic conformational change,
exposing this glutamic acid as the HA2 stem folds back on itself
[85]. Assuming HA of influenza B virus undergoes a similar
conformational change, S465 would be exposed to kinases in the
fusion conformation; indeed, it is present in a conserved S-x-E
casein kinase recognition motif. It is interesting to note that the
phosphorylated form of this residue would then have similar
physicochemical properties to the glutamic acid exposed in
refolded influenza A virus HA. However, it seems unlikely that
fusion conformation HA is a major component of the purified
virus preparation, and the functional significance of this residue is
unclear.
For the NA of the influenza A virus WSN (N1 subtype), we
detected phosphorylation (along with an artefactual carbamido-
methylation of C168) which could be plausibly assigned to one of
three serines: residues 160, 164 or 166. All three serines are highly
conserved in N1 neuraminidases (Table 1). When the NA
consensus sequences of different influenza A virus subtypes and
influenza B virus lineages are compared, S160 is not conserved,
S164 is serine for all subtypes and lineages, and S166 is either
serine or threonine (data not shown). S166 is buried and so is
unlikely to be phosphorylated (Figure 5A [86]). S160 is positioned
at the interface of two head domains in the NA tetramer
(Figure 5A). Assuming that all structural NA is assembled into
tetramers, this site would presumably only be accessible to kinases
prior to tetramer assembly in the endoplasmic reticulum. S164, as
well as being conserved in all influenza A and B virus NAs, is
positioned in a more obviously accessible location. It lies at the
base of a pocket containing the neuraminidase active site, and is
one of the supporting framework residues of the active site
(Figure 5A, B) [87]. Phosphorylation would interfere with its polar
contact with the framework residue E212, and the negative charge
it introduces could potentially disrupt interactions with sialic acid,
reducing the ability of newly formed viruses to leave the cell.
Mutations shown to confer neuraminidase inhibitor resistance lie
on the opposite side of the pocket to S164 [88], suggesting that
phosphorylation would not affect known mechanisms of drug
resistance.
Phosphorylation of the Polymerase and Nucleoprotein
Despite previous reports that PB1 and PA were phosphopro-
teins within infected cells [14,20,25], we did not detect phosphor-
ylations in the polymerase proteins of any of the purified viruses,
whether or not optimised conditions were used (Table S2). Two
alternative approaches were used to analyse the polymerase
proteins of WSN in 293 T cells. In one approach, cells were
infected with a modified WSN virus which expressed PB2 protein
fused to a C-terminal tag [89]. The tag was used to isolate PB2-
containing complexes, including RNPs (Figure S1B). In a second
approach, the polymerase proteins were expressed by transfection
and a tag fused to the C-terminus of PB1 was used to purify it from
cell lysates, along with bound PA and PB2 (Figure S1C). In
infected cells we detected phosphorylation of PB2 at S742 and of
PA at S224 or S225, with S225 the more likely assignment. We
also detected phosphorylation of NP, as discussed below (Table 1).
In the transfected cells we identified a single phosphopeptide,
derived from PB1, with phosphorylation of T223 (as well as
artefactual oxidation of M227; Table 1). The failure to detect
phosphorylated polymerase protein in virions suggests that only
non-phosphorylated polymerase proteins are packaged into the
virus, though this may merely reflect a stochastic failure to detect
the relevant phosphopeptides in the samples analysed.
In PB2, S742 forms part of a flexible C-terminal tail containing
the protein’s bipartite NLS [90,91]. This tail unfolds to allow the
protein to bind to alpha importins (Figure 6A, B) [91]. The
phosphorylation site consists of highly conserved residues between
the two parts of the NLS. This arrangement is conserved in
influenza B viruses and apparently also in influenza C viruses,
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suggesting a functional role (Figure 6C). As discussed above,
phosphorylation at or near to NLSs regulates interactions with
nuclear import factors [50–52]. In the case of PB2, a co-crystal
structure of the C-terminus of PB2 bound to importin a5 [91]
shows that S742, although in a flexible region not resolved in the
structure, is positioned near to the surface of the importin
(Figure 6B; the adjacent 741 residue is present in the structure
close the importin surface). Phosphorylation of this residue is
therefore highly likely to affect importin binding, thereby
regulating the nuclear import of PB2. Whether phosphorylation
would promote or inhibit nuclear import is unclear from the
structure alone, and as the approach used here does not
distinguish monomeric PB2, prior to nuclear import, from PB2
present in an RNP, the stage at which this regulation is applied
cannot yet be determined.
In PB1 T223 is highly conserved, and serines or threonines are
conserved at the corresponding residue in influenza B and C
viruses (Figure 6C). In the primary sequence of PB1 T223 is
between the NLS/RanBP5-binding site [92,93] and the core
promoter binding and polymerase motifs [94–98], suggesting a
possible role in regulating nuclear import or RNA binding.
However, as the structure and function of this region of PB1 are
unknown it is hard to draw firm conclusions about the effect of its
phosphorylation.
In PA S224 is highly conserved in influenza A viruses. In
contrast, S225 (a better match to the spectrum, and in an S-x-E
casein kinase consensus) is only present in 69% of isolates, with
most of the remainder having cysteine at this position (Table 1).
Conserved serines or threonines can be found in a similar position
in influenza B and C viruses (Figure 6C). TheS224/S225 site is
positioned in a region of unknown structure and function, between
the N-terminal endonuclease domain and the C-terminal PB1-
interacting domain of PA [99]. In a previous analysis of possible
phosphorylation sites in influenza A/Victoria/3/75, a strain in
which position 225 is cysteine, mutation of S224 to alanine was
shown not to affect RNP activity or the apparent proteolytic
activity of PA [25]. The effect of phosphorylation at this site is
therefore currently unclear.
The nucleoprotein (NP) is, after M1, the most abundant protein
in the virus (Figure 1A) [44], and is known to be a phosphoprotein
Figure 5. Location of phosphorylated residues in neuramini-
dase. (A) The position of S160/S164/S166 in the head domain of an N1-
subtype NA, viewed facing the virion surface (PDB 3BEQ [86]). Head
domains of the NA tetramer are shown in light blue and pink. (B) The
position of S164 in the NA active site, with catalytic residues in yellow
and framework residues in pink.
doi:10.1371/journal.ppat.1002993.g005
Figure 6. Location of phosphorylated residues in the polymer-
ase. The position of S472 in the C-terminal tail of PB2 when (A)
unbound (PDB 2GMO [91]) and (B) bound (PDB 2JDQ [91]) to importin
a5. PB2 is shown in light blue and the importin in gold. In the bound
form residues 742–747 are not resolved in the structure, and are
indicated by a dotted line; the position of S742 has been estimated. (C)
Portions of the consensus sequences of PB2, PB1 and PA from influenza
A, B and C viruses. Colours are as in Figure 2; basic residues of the
bipartite NLS of influenza A virus PB2, and orthologous residues in the
influenza B and C virus sequences, are blue.
doi:10.1371/journal.ppat.1002993.g006
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[6,17,18]. Phosphorylation occurs at multiple sites, predominantly
serines, and can vary between viral strains and host species, as well
as during the course of an infection [7,12,13]. Serine 3 (the residue
is, very unusually, threonine in WSN), accounts for the majority of
N-terminal phosphorylation in infected cells [7], but is not
detected in virions [13]. Additional phosphorylation has been
mapped to the C-terminal 196 residues of the protein [7].
For WSN virus without the use of optimised conditions,
phosphorylation was readily detected at either S402 or S403
(Table 1). We detected the same phosphorylation in WSN NP
from cell lysates, both when RNPs were purified from infected
cells, and when an N-terminal tag was used to purify NP expressed
by transfection in uninfected 293 T cells (Figure S1B, C; Table
S2). While S402 is highly conserved, S403 is an unusual feature of
WSN and is more typically an alanine (Table 1). In the PR8-
derived NP of the influenza A CVVs, for which residue 403 is an
alanine, S402 was unambiguously phosphorylated (Table S2). It is
likely that this residue accounts for much of the previously
observed phosphorylation of the C-terminal portion of NP [7].
Optimised mass spectrometry conditions allowed us to detect
additional sites of NP phosphorylation in the influenza A virus
WSN. In virions, phosphorylation was detected for S9/Y10, S165
(with an artefactual carbamidomethylation of C164), S457 and
T472/S473. In RNPs purified from infected cell lysates phos-
phorylation was detected at S9/Y10, S165 (again with an
artefactual carbamidomethylation), Y296/S297, and S377/S378.
All of these residues are highly conserved in influenza A viruses,
with the exception of S377 (59% conserved, with the majority of
other usages being asparagines), and S473 (which is typically
asparagine, and which has been speculated to play a role in strain-
specific phosphorylation of NP [13]). Peptides containing residue 3
were hard to identify due to tryptic cleavage sites present very close
to the N-terminus (K4, K7, R8). However, when a peptide
containing T3 was identified in purified virions it was N-terminally
modified but not phosphorylated (Tables 3, S3), consistent with
previous observations that residue 3 was not phosphorylated in
virions, and that phosphorylation of this residue may be strain-
specific [13].
NP has been reported to contain multiple NLSs [100], but the
primary signal for nuclear import of free NP and of RNPs is an
unconventional NLS located in the N-terminus [101–103].
Treatment with the phosphorylation stimulator TPA and the
protein kinase inhibitor H7 showed that the nuclear accumulation
of NP is inhibited by phosphorylation [101]. Mutational analysis
suggests that phosphorylation of S3, which is adjacent to the N-
terminal NLS of NP, inhibits its nuclear accumulation [8]. S9 and
Y10, whose phosphorylation is detected here, are within the
sequence of the N-terminal NLS [101,102], and their phosphor-
ylation would also be expected to inhibit nuclear import [104]. It
therefore appears that phosphorylation may regulate the nuclear
import not only of M1 and PB2 (and potentially of NS1 and PB1)
but also of NP, and through it of the viral genome.
The structure of the N-terminus of NP, including S3/T3, S9
and Y10, is not known. All other sites detected in this study are
located on the surface of the NP monomer (Figure 7A), supporting
their identification as phosphorylated residues. As none of the
residues were part of the RNA-binding groove of NP [105], it is
unlikely that phosphorylation would interfere directly with RNA
binding. In the structure of a WSN NP trimer, S165 and S457
participate in intermolecular van der Waals bonds, and S165,
S402, S403 and S457 participate in intermolecular hydrogen
bonding [105] – interactions that might be disrupted by
phosphorylation. Of particular interest, S402/S403 and S165
are present in the ‘tail loop’ and ‘groove’ (respectively) which
mediate NP oligomerisation (Figure 7B) [105,106]. Phosphoryla-
tion could therefore plausibly interfere with the oligomerisation of
NP.
In influenza B viruses we detected phosphorylation of S50 even
without the use of optimised conditions (Tables 2, S2). This residue
is found in a disordered N-terminal region with no homology to
influenza A virus NP sequences [107,108] and, despite the
relatively high sequence variation of this region (data not shown),
is absolutely conserved. Using optimised mass spectrometry
conditions we identified additional phosphorylation sites, at
T55/T56/S57/S58, S223, Y352/Y357/Y363, S459/S463/S465
and S486 (Figure 7A). With the exception of S57, which is an
isoleucine in 20% of isolates, all of these residues are highly
conserved (Tables 2, S2). Despite significant differences in the
primary sequences of NP from influenza A and B viruses, the
locations of several phosphorylation sites are conserved in the
tertiary structures of influenza A and B viruses [105,108]. Y296/
S297 (A) and Y352-Y363 (B) are both predicted to be targets of the
kinase Cdc2 (Tables 1, 2 and S2) and occupy similar positions on a
loop in the tertiary structure (Figure 7A), though the functional
significance of this site is unclear. Strikingly, in the tail loop/
groove region, phosphorylation is detected in both genera of virus
at conserved serines in the N-terminal end of the tail loop (S402/
S403 (A), S459/S463/S465 (B); Figure 7B), and at a conserved
serine within the groove (S165 (A), S223 (B); Figure 7B).
The Effects of Mutating Phosphorylation Sites in
Influenza A Virus Nucleoprotein
To assess the importance of phosphorylation sites found in NP
in influenza A virions, we introduced alanine mutations into WSN
viruses at the N-terminus, in the tail loop/groove oligomerisation
domain, and in the C-terminus (Figure 8A). Mutations at the N-
terminus that removed phosphorylation sites had pronounced
effects on viral growth kinetics: S9A reduced viral titre by
approximately 10-fold at 30 h post-infection (p.i.), and Y10A by
100-fold. In contrast, and consistent with their distance from
known functional sites in NP, mutations at the C-terminus had
little or no effect on viral growth: S457A caused a slight reduction
in titre (3-fold at 30 h p.i.), whereas T472A had no effect.
In the tail loop-groove region, virus with the S165A mutation
could not be produced in three separate attempts, despite the
generation of WT virus, suggesting that this residue may be
essential for viral growth. Despite phosphorylation of S402 being
readily detected, an S402A mutation caused a relatively small
defect in growth (5-fold at 30 h p.i.). Replacing the residue with
glutamic acid, which is approximately similar in size and charge to
phosphoserine, reduced the titre by approximately 20-fold at 30 h
p.i., suggesting that although S402 phosphorylation is readily
detected in the virion, constitutive phosphorylation of this residue
is not optimal for viral growth. Although S403 is an alanine in the
majority of influenza A virus strains, an S403A mutation caused a
10–100-fold growth defect at 30 h p.i., suggesting a specific
requirement of WSN for serine at this position. A similar defect
was seen when both S402 and S403 were mutated to alanines,
removing the phosphorylation sites entirely (data not shown).
To assess the roles of NP phosphorylation sites in transcription
and replication (including the S165 site, which could not be
mutated in a virus) we performed RNP reconstitutions in 293 T
cells (Figure 8B). The majority of the mutations did not reduce the
transcription or replication of the genome – indeed, very small
though statistically significant increases in activity were seen for
the S9A and S457A mutations. This suggests that the growth
defects caused by these mutations relate to NP functions not
required for transcription and replication during RNP reconstitu-
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Figure 7. Location of phosphorylated residues in the nucleoprotein. (A) Location of phosphorylated residues in NP of influenza A virus WSN
(PDB 2IQH [105]) and influenza B virus (PDB 3TJ0 [108]). The structures do not include N-terminal residues, including S9 and Y10 of influenza A virus
NP and S50 and T55-S58 of influenza B virus NP. The N-termini of the resolved structures and tail loops are indicated; in the orientation shown, the
RNA-binding grooves are on the far side of the molecules. (B) The oligomerisation of NP of influenza A virus or influenza B virus via the tail loop (blue)
and groove (pink), with phosphorylated residues highlighted.
doi:10.1371/journal.ppat.1002993.g007
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tions, for example viral entry, trafficking to the cell surface, viral
assembly or immune regulation. The only residue which appeared
to be important for RNP activity was S165. Mutating this residue
to alanine caused a moderate decrease in RNP activity, but the
phosphomimetic glutamic acid mutation caused a substantial and
significant reduction in both transcription and replication. This is
consistent with structural predictions, which suggest that phos-
phorylation of this residue would be inhibitory to NP oligomerisa-
tion and hence to RNP assembly (Figure 7B). The presence of a
phosphorylation site in the oligomerisation groove of NP is a
conserved feature of both influenza A and B viruses (Figure 7B).
This could be due to a structural requirement for serine at this
position, with phosphorylation simply a deleterious side effect.
However, it is interesting to note that the reversible nature of
phosphorylation could provide the virus with a mechanism for
regulating NP oligomerisation and RNP assembly.
Concluding Remarks
Mass spectrometry allows the detection of specific sites of
protein phosphorylation. By applying this technique to a selection
of influenza A viruses and an influenza B virus we have identified
39 phosphorylation sites, 36 of them novel. Unmodified peptides
were also detected, consistent with phosphorylation typically
acting on a subset of the proteins present in the cell. Strikingly,
we found that a number of phosphorylation sites were conserved
between different strains and even genera, underlining the
fundamental importance of phosphorylation in the life cycles of
influenza viruses.
Patterns of phosphorylation were similar between WSN grown
in MDBK cells and reassortants of the similar PR8 virus grown in
embryonated eggs and MDCK cells. This suggests that the
similarities between these viruses are more important in
determining phosphorylation patterns than the substantial differ-
ences between the hosts in which they were grown. From this it is
reasonable to infer that the phosphorylation sites reported in this
study will, in most cases, be similar to those found in other hosts,
including in natural infections. Of the phosphorylation sites
detected in PR8 reassortants only one was not also detected in
WSN (M1 T37, detected in an MDCK-grown virus). As detection
of phosphorylation by mass spectrometry is a stochastic process we
consider this likely to reflect sampling variation rather than a
difference in phosphorylation patterns. For the same reason,
failure to detect phosphorylation at particular sites in this study (for
example, at residues orthologous to phosphorylation sites in
influenza A and B virus M1; Figure 2A) does not exclude
phosphorylation at these positions.
By considering the position of sites of phosphorylation with
respect to known structural and functional motifs we have been
able to suggest cases where phosphorylation is likely to affect viral
protein function. Phosphorylation appears to regulate three broad
categories of function: viral entry and exit (HA and NA), nuclear
localisation (PB2, NP, M1, NEP, and possibly PB1 and NS1), and
multimerisation (NP, M2 and NS1). In addition, a number of
phosphorylations did not have an obvious function, and it is likely
that some of these phosphorylations are non-essential, arising
through interactions with cellular kinases that confer no fitness
advantage to the virus [109]. This has previously been suggested
for phosphorylation of M2 S64 [11,21], though we identify here
an alternative, though relatively uncommon, phosphorylation of
T65 which may compensate for S64 loss.
The functions of a number of phosphorylation sites in NP of the
influenza A virus WSN were tested experimentally, and were
found to contribute to viral growth in cell culture and to RNP
activity to varying extents. In arguing for a functional role for
phosphorylation, studies of this sort are suggestive, though further
studies will be required to address the possibility that the mutations
may introduce unrelated structural changes, or that viral fitness
and/or RNP activity may depend on the residues being present
but unphosphorylated. However, by combining arguments from
evolutionary conservation, structural context and experimental
evidence, a convincing case can be made for the existence of
multiple functional phosphorylation sites.
Figure 8. Effect of mutating phosphorylated residues in the
nucleoprotein. (A) WSN viruses were generated containing the
indicated mutations in NP. MDBK cells were infected at an MOI of 0.001,
and virus harvested at the indicated time points. The mean and range
of two experiments, or, for S402A and S402E, the mean and standard
deviation of 4 experiments, is shown. For S402A and S402E differences
from WT were tested by Student’s unpaired 2-tailed t-tests at each time
point; for both mutants the differences at 8 h are not significant, those
at 24 h significant at p,0.05 and those at 30 h significant at p,0.005.
(B) To assess the function of mutated NP proteins in transcription and
replication, RNP reconstitutions were performed in 293 T cells and RNA
species at 22 h post-transfection measured by primer extension and
autoradiography. A representative image is shown, along with the
mean and s.d. of 4 experiments, relative to WT. Differences from WT
were tested using one-sample t-tests: * p,0.05, *** p,0.0005.
doi:10.1371/journal.ppat.1002993.g008
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Like most viral proteins NP is multi-functional [110], and, as
discussed above, its phosphorylation state has been shown to
change during the course of an infection. This study concentrates
on proteins packaged into viral particles, but it is important to
recognise that these proteins may be subject to a series of
phosphorylation and de-phosphorylation events during the viral
life cycle. As such, the patterns of phosphorylation reported here
represent, for the most part, the final stage in a series of
interactions, functional and non-functional, between the proteins
of influenza viruses and the kinases and phosphatases of the cells
they infect. The increasing power of mass spectrometry to identify
phosphorylation patterns in complex samples will make it possible
in the future to map the dynamics of phosphorylation over the
entire course of an infection [24].
Phosphorylation provides a promising target for antiviral
chemotherapy, particularly as targeting cellular kinases reduces
the capacity for viral escape mutations. Treatment of cells with
protein kinase inhibitors interferes with multiple stages in the
influenza virus life cycle, including nuclear import, transcription,
protein synthesis, nuclear export and viral budding [69,111–114].
Some of these effects are due to changes in phosphorylation of host
factors [115,116], but altered phosphorylation of viral proteins also
has direct effects on the viral life cycle. It is interesting to note that
some of the kinases predicted to phosphorylate sites found in this
study, in particular protein kinase C, are targeted by kinase
inhibitors that are known to affect influenza viruses (Tables 1, 2
and S2; [101,111,112]). Phosphorylation stimulators and kinase
inhibitors affect the nuclear import of NP, and kinase inhibitors
prevent the nuclear export of NEP, as discussed above. A number
of kinase inhibitors, some already approved for cancer treatment,
are being investigated as antiviral drugs [117,118], including as
treatments for influenza [119,120]. Narrow-spectrum kinase
inhibitors such as these, effective at sub-toxic concentrations,
provide a promising route for antiviral therapy. The identification
in this study of specific and highly conserved phosphorylation sites
suggests that influenza viruses have a fundamental requirement for
cellular kinases (predictions of which are given Tables 1, 2 and S2)
and therefore provides a foundation for the targeted development
of novel antiviral strategies.
Materials and Methods
Cells, Viruses and Plasmids
Madin-Darby Bovine Kidney epithelial (MDBK) cells, Madin-
Darby Canine Kidney epithelial (MDCK) cells and 293 T human
embryonic kidney cells were maintained at 37uC and 5% CO2 in
Modified Eagle Medium with Earle’s salts (MEM; PAA) supple-
mented with 2 mM L-glutamine and 10% fetal calf serum (FCS).
Influenza A/WSN/33 virus (WSN) [121] was cultured on
MDBK cells in MEM supplemented with 2 mM L-glutamine and
0.5% fetal calf serum (FCS). Candidate Vaccine Viruses (CVVs)
were a kind gift of Dr Othmar Engelhardt (National Institute of
Biological Standards and Controls, UK). NIB-74xp and NYMC
X-187 have HA and NA genes of the influenza viruses A/
Christchurch/16/2010 (A(H1N1)pdm09) and A/Victoria/210/
2009 (H3N2), respectively, with the remaining genes from
influenza A/Puerto Rico/8/1934 (PR8). NYMC X-181 has HA,
NA and PB1 genes of influenza A/California/7/2009
(A(H1N1)pdm09) with the remaining genes from PR8. Influenza
B/Brisbane/60/2008 virus is an egg-adapted clinical isolate.
CVVs were propagated in embryonated chicken eggs. Addition-
ally, NIB-74xp was cultured in MDCK cells in MEM with 2 mM
L-glutamine, 0.14% bovine serum albumin (Sigma) and 0.75 mg/
ml bovine pancreatic trypsin (Sigma). Plasmids for use in affinity
purification [122–124], RNP reconstitution [125] and reverse
genetics [121] have been described previously. Specific mutations
were introduced into the plasmids by site-directed mutagenesis
and confirmed by sequencing. Mutated WSN viruses were
generated by reverse genetics, as previously described [121,126].
Influenza A/WSN/33 PB2-Cstrep was generated using pPR7-
PB2-Cstrep [89,122] in place of pPOLI-PB2.
Plaque assays were performed on MDBK cells using standard
techniques. RNP reconstitutions were performed in 293 T cells
using segment 6 (NA) vRNA as a template, and RNA accumu-
lation measured by primer extension, PAGE, autoradiography and
phosphorimaging, as described previously [125].
Affinity Purifications
Affinity purifications of PB1-TAP using a Tandem Affinity
Purification (TAP) tag [123,124] were carried out in transfected
293 T cells as previously described. To purify RNPs, 293 T cells
were infected with influenza A/WSN/33 PB2-Cstrep [89,122] at
an MOI of 5. At 6 h post-infection (p.i.) cells were harvested and
resuspended in phosphate buffered saline, pelleted at 450 g/
5 min/4uC, and placed on a rotating wheel for 1 h at 4uC in lysis
buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 33% glycerol,
0.5% NP-40 and 1 mM dithiothreitol with protease inhibitor
cocktail (Roche)). The soluble fraction was separated by centrifu-
gation at 17 000 g/3 min/4uC, diluted 1:5 with binding buffer
(20 mM Tris-HCl pH 8.0, 200 mM NaCl and protease inhibitor
cocktail (Roche)) and incubated overnight at 4uC with 200 ml of
50% suspension Strep-Tactin Superflow high capacity resin (IBA
GmbH). The resin was washed four times with wash buffer
(100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1%
NP-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride), and
proteins were eluted in 2 ml of elution buffer (100 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 10%
glycerol, protease inhibitor cocktail (Roche), 2 mM d-desthiobio-
tin) for 2 h on a rotating wheel at 4uC. Elution fractions were
subsequently concentrated using Amicon Ultra-4 (3K MWCO)
centrifugation devices.
Virus Purification
Viruses grown in cell culture were harvested from the growth
media of four T175 flasks of infected cells (120 ml; 109–1010
plaque-forming units (PFU) of virus for WSN) at 2 days p.i. The
medium was clarified by low-speed centrifugation (2000 g/30 min
then 18 000 g/30 min, at 4uC), then layered onto a cushion of
30% sucrose in NTC (100 mM NaCl, 20 mM Tris-HCl pH 7.4,
5 mM CaCl2) and pelleted by ultracentrifugation (112 000 g/
90 min/4uC in an SW 28 rotor (Beckman Coulter)). Pellets were
resuspended in NTC and spun through a 30–60% sucrose
gradient in NTC (209 000 g/150 min/4uC in an SW 41 Ti rotor
(Beckman Coulter)) to produce a visible band of virus which was
drawn off with a needle and pelleted through NTC (154 000 g/
60 min/4uC in an SW 41 Ti rotor) and resuspended in a small
volume of NTC (typically 120 ml, containing 108–109 PFU WSN).
A similar method was used to purify CVVs from infected eggs.
Briefly, infected allantoic fluid was harvested, filtered and mixed
with sodium azide. Virus was pelleted by ultracentrifugation,
resuspended and spun on 10–40% sucrose gradients to produce a
visible band of virus which was harvested and pelleted by
ultracentrifugation. Samples of virus were taken to determine
plaque titre; separated by SDS-PAGE and Coomassie or Silver
stained according to standard techniques; or fixed with 2.5%
glutaraldehyde, 2% paraformadehyde and 0.1% picric acid in
100 mM cacodylate buffer (pH 7.0), adsorbed onto formvar-
coated grids, negative-stained with 2% aqueous uranyl acetate and
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examined by transmission electron microscopy using a FEI Tecnai
12 electron microscope.
Mass Spectrometry
Samples of purified virus or PB2-Cstrep purified material were
prepared for mass spectrometry by boiling in Laemmli buffer and
running a short distance into a polyacrylamide gel (typically a
precast 8–16% Precise Protein Gel (Thermo Scientific)) to remove
detergent and salts; the entire sample was then cut out of the gel
with a clean scalpel. As an alternative method, some WSN samples
were boiled in 1.25% SDS, precipitated in 220uC acetone, and
resuspended in 8 M urea, 25 mM ammonium bicarbonate. Whole
cell lysates and TAP-purified samples were separated by SDS-
PAGE and stained with Coomassie; bands of the appropriate
electrophoretic mobility were excised with a clean scalpel. Samples
were then washed with 50 mM ammonium bicarbonate in 50%
acetonitrile, reduced with 10 mM DTT and 55 mM iodoaceta-
mide or chloroacetamide and digested with 0.5 mg trypsin
(Promega) at 37uC for 16 h. Peptides were extracted with 0.1%
formic acid in 50% acetonitrile, lyophilised in a SpeedVac
(Thermo Savant) and desalted using an in-house manufactured
C18 purification tip. Enrichment for phosphopeptides using TiO2
[127] or IMAC [128] were carried out essentially as described
previously; flow-through samples were also retained and analysed,
and the data pooled with that of the enriched sample. Samples
were lyophilised and stored at 220uC, then dissolved in 0.1%
formic acid prior to mass spectrometry analysis.
All LC-MS/MS experiments were performed using either an
Ultimate 3000 nano HPLC system (Dionex, Camberley, UK) run
in direct injection mode, coupled to an LTQ XL Orbitrap mass
spectrometer or a Q Exactive mass spectrometer (Thermo
Electron, Hemel Hempstead, UK). Separation of peptides was
performed by reverse-phase chromatography using a 15 cm (LTQ
XL Orbitrap) or 25 cm (Q Exactive) by 75 mm inner diameter
picotip analytical column (New Objective, Woburn, MA, USA),
packed in house with Reprosil-Pur C18-AQ phase, 3 mm particle
size (Dr Maisch, Germany), at a flow rate of 300 nl/min. Samples
were typically resolved on a 120 min gradient. The LTQ XL
Orbitrap mass spectrometer was operated in a ‘‘Top 5’’ and the Q
Exactive in a ‘‘Top 10’’ data-dependent acquisition mode. Charge
state +1 ions were rejected from selection and fragmentation and
dynamic exclusion with 40 s was enabled.
Analysis of Mass Spectra
Mass spectra were analysed using the Central Proteomics
Facilities Pipeline (CPFP) [31]. For purified virions data from
repeat experiments were merged to increase sample coverage; for
searches of CVVs data from two injections of sample were
merged. Peptide spectral matches were made to custom databases
that concatenated the proteome of the relevant virus with that of
the host (Bos taurus for MDBK cells, Canis lupus familiaris for
MDCK cells, Gallus gallus for chicken eggs and Homo sapiens for
293 T cells) and with common contaminants and decoy
sequences. For WSN the viral proteome was expanded to include
experimentally confirmed and hypothetical proteins, as well as a
translation of all six complete forward and reverse-sense reading
frames from each viral segment. To identify peptides, CPFP uses
iProphet [129] to combine searches made with Mascot (Matrix
Science, London, UK), OMSSA [130] and X!TANDEM [131],
with peptide identifications validated using PeptideProphet [132].
Combined protein identifications were then assigned using
ProteinProphet [133] with a 1% false discovery rate. Searches
were made for peptides with up to two missed cleavages and with
common post-translational modifications including phosphoryla-
tion at S, T or Y. The Modification Localisation Score (ModLS)
algorithm within CPFP was applied to phosphopeptide identifi-
cations to assess the confidence of phosphorylation site assign-
ments. MS/MS search engines may not always assign phosphor-
ylation at the site that is most probable given the spectral
evidence, since their emphasis is on peptide identification rather
than phosphorylation localisation. The ModLS algorithm re-
assigns phosphorylation sites when the search-engine reported
assignment is a poorer fit to the spectral evidence than an
alternative localisation. PTMScores are calculated as previously
described [32], with the exception that the peak depth per
100 m/z units is varied between 1 and 10, and the highest
scoring result obtained is used. ModLS assesses the confidence
with which phosphorylation sites can be assigned on a peptide by
the difference between the highest and second-highest
PTMScores calculated for all possible localisations of phosphor-
ylation on a given peptide. Assessment of the ModLS algorithm
using spectra from mixtures of known phosphopeptides [134]
shows that a ModLS of ,14 gives a false localisation rate of ,1%
(data not shown). As N-terminal modifications are not reported
correctly in the version of CPFP used, peptide spectra matched to
N-terminal peptides by Mascot were searched manually. All
spectra of reported modified peptides were manually inspected,
and representative spectra are given in Figure S3.
Sequence and Structural Analysis
Full-length influenza protein sequences were downloaded from
GISAID (http://platform.gisaid.org) or from the NCBI influenza
virus resource (http://www.ncbi.nlm.nih.gov/genomes/FLU/
FLU.html) and aligned with MAFFT [135] using the FFT-NS-2
method. The number of sequences analysed for each protein is
given in Table S4. Alignments were edited using BioEdit [136]
and consensus sequences were generated with Jalview [137].
Protein structures were visualised using PyMOL (Schro¨dinger
LLC); predictions of secondary structure were made using JPred 3
[138]. Phosphorylation sites were predicted using NetPhos 2.0 and
NetPhosK 1.0 [58].
Supporting Information
Figure S1 Purification of viral proteins. (A) Candidate
vaccine viruses (CVVs) were purified from embryonated chicken
eggs or the culture medium of infected MDCK cells, separated by
SDS-PAGE and silver stained. (B) 293 T cells were infected with
A/WSN/33 PB2-Cstrep, and affinity purification was used to
purify PB2-Cstrep and associated proteins from cell lysates.
Proteins were separated by SDS-PAGE and silver stained. Key
proteins are identified by electrophoretic mobility. (C) Affinity
purification of PB1-TAP (with co-purifying PB2 and PA) and,
separately, TAP-NP from transfected 293 T cells. Protein was
separated by SDS-PAGE and stained with Coomassie Brilliant
Blue; the indicated viral proteins were excised from the gel and
submitted for LC-MS/MS.
(TIF)
Figure S2 Coverage of sequences. The full sequences of all
proteins to which peptides were matched, with peptides assigned
by CPFP shaded. Peptides with N-terminal acetylation (Table S3)
were scored separately and are not necessarily shown.
(PDF)
Figure S3 Representative spectra. Fragment ion spectra for
N-terminal peptides and for phosphorylated peptides, annotated
by Mascot or CPFP. The clearest spectrum showing each
modification referred to in the text is presented (including
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overlapping peptides and unmodified peptides where available).
Each spectrum was manually inspected.
(PDF)
Table S1 Protein sequence coverage.
(DOC)
Table S2 Summary of phosphopeptides.
(DOC)
Table S3 N-terminal modifications.
(DOC)
Table S4 Number of sequences used in alignments.
(DOC)
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